The Kinetics of Inflammation-Related Proteins and Cytokines in Children Undergoing CAR-T Cell Therapy—Are They Biomarkers of Therapy-Related Toxicities?
Authors:
- Paweł MarschollekPMPaweł Marschollek
- Karolina LiszkaKLKarolina Liszka
- Monika Mielcarek-SiedziukMMMonika Mielcarek-Siedziuk
- Iwona Dachowska-KałwakIDIwona Dachowska-Kałwak
- Natalia HazeNHNatalia Haze
- Anna PanasiukAPAnna Panasiuk
- Igor OlejnikIOIgor Olejnik
- Tomasz JarmolińskiTJTomasz Jarmoliński
- Jowita FrączkiewiczJFJowita Frączkiewicz
- Zuzanna GamrotZGZuzanna Gamrot
- Anna RadajewskaARAnna Radajewska
- Iwona Bil-LulaIBIwona Bil-Lula
Open Access
- 21 July 2024
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 12 (7) , 1622
Abstract
CD19-targeted CAR-T cell therapy has revolutionized the treatment of relapsed/refractory (r/r) pre-B acute lymphoblastic leukemia (ALL). However, it can be associated with acute toxicities related to immune activation, particularly cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Cytokines released from activated immune cells play a key role in their pathophysiology. This study was a prospective analysis of proinflammatory proteins and cytokines in children treated with tisagenlecleucel. Serial measurements of C-reactive protein, fibrinogen, ferritin, IL-6, IL-8, IL-10, IFNγ, and TNFα were taken before treatment and on consecutive days after infusion. The incidence of CRS was 77.8%, and the incidence of ICANS was 11.1%. No CRS of grade ≥ 3 was observed. All complications occurred within 14 days following infusion. Higher biomarker concentrations were found in children with CRS grade ≥ 2. Their levels were correlated with disease burden and CAR-T cell dose. While cytokine release syndrome was common, most cases were mild, primarily due to low disease burden before lymphodepleting chemotherapy (LDC). ICANS occurred less frequently but exhibited various clinical courses. None of the toxicities were fatal. All of the analyzed biomarkers rose within 14 days after CAR-T infusion, with most reaching their maximum around the third day following the procedure.Keywords
Funding Information
- Saving Kids With Cancer Foundation (FNRD.C200.21.002)
This publication has 35 references indexed in Scilit:
- Intrathecal hydrocortisone for treatment of children and young adults with CAR T‐cell immune‐effector cell‐associated neurotoxicity syndromePediatric Blood & Cancer, 2023
- CAR-T Cell Therapy: the Efficacy and Toxicity BalanceCurrent Hematologic Malignancy Reports, 2023
- The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cellsImmunology Letters, 2019
- Glial injury in neurotoxicity after pediatric CD19‐directed chimeric antigen receptor T cell therapyAnnals of Neurology, 2019
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerationsClinical & Translational Immunology, 2019
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockadeNature Medicine, 2018
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cellsNature Medicine, 2018
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicitiesNature Reviews Clinical Oncology, 2017